1675.90
-1.37%
Axis Direct
Q2FY18 EBITDA grew 32% YoY (~15% above our estimate) led by 25% YoY growth in topline (15% YoY on standalone basis). EBITDA margin improved 210 bps YoY driven by operating leverage.
Promoters unpledged 1.58% of shares in last quarter. Total pledge stands at 16.93% of promoter holdings
More from Eris Lifesciences Ltd.
Recommended